<DOC>
	<DOCNO>NCT00430729</DOCNO>
	<brief_summary>The purpose study investigate effect 500mcg roflumilast v placebo exacerbation rate pulmonary function well quality life patient chronic obstructive pulmonary disease ( COPD ) .</brief_summary>
	<brief_title>Effect Roflumilast Exacerbation Rate Patients With Chronic Obstructive Pulmonary Disease . Ratio-Study . ( BY217/M2-112 )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Main FEV1/FVC ratio ( postbronchodilator ) ≤70 % FEV1 ( postbronchodilator ) ≤50 % predict Current smoker exsmoker Clinically stable COPD indicate exacerbation change COPD treatment within 4 week prior baseline Availability chest xray date maximum 6 month prior study baseline visit B0 willingness chest xray perform baseline Main COPD exacerbation indicate treatment systemic glucocorticoid stop 4 week prior baseline Lower respiratory tract infection resolve 4 week prior baseline Diagnosis asthma and/or relevant lung disease Known alpha1antitrypsin deficiency Need longterm oxygen therapy define ≥16 hours/day</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Roflumilast</keyword>
</DOC>